zurück

Atezolizumab (new indication: non-small cell lung cancer (NSCLC), PD-L1 expression ≥ 50 %, EGFR/ALK negative, adjuvant therapy following resection and chemotherapy)

 

Subject:

  • Active Sustance: Atezolizumab
  • Name: Tecentriq®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Roche Pharma AG

 

Time table:

  • Start: 15.07.2022
  • Final decision by G-BA: 05.01.2023
  • The decision remains valid until: 01.04.2024

 

Final decision:

  • Hint for a non-quantifiable additional benefit